Company: WKC
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0000950170-25-058752
Chunk: 84

Company: WORLD KINECT CORP
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 84
---
, all equity-based awards granted under the 2025 Plan shall be subject to a minimum vesting or performance period of one (1) year (excluding, for this purpose, any substitute awards and shares of Stock issued pursuant to a participant’s election to receive shares of Stock in lieu of cash compensation); provided, however, that, notwithstanding the foregoing, an aggregate of up to 5% of the maximum number of shares of Stock available for delivery pursuant to awards granted under the 2025 Plan may be used for awards that do not comply with such minimum vesting requirements at the time of the grant. The minimum vesting period does not apply to the Committee’s discretion to provide for accelerated exercisability or vesting of any award upon the death or disability of a participant. In addition, the minimum vesting requirement would be deemed satisfied with respect to any award granted to a non-employee member of the Board if such award vests on the earlier of the one-year anniversary of the date of grant and the next annual shareholder meeting.

Adjustments

In the event of any equity restructuring of the Company, such as a stock dividend, stock split, combination of shares, spin-off, reverse stock split, split-up, rights offering, recapitalization or non-recurring cash dividend or other distribution (whether in the form of shares of Stock, other securities or other property), the Committee shall adjust each award to prevent dilution or enlargement of the rights of the holder with respect to such award. In addition, in the event of any merger, consolidation, combination, exchange of shares or any similar corporate transaction or event described above (including any Change of Control), the Committee shall adjust each award in order to preserve the benefits and potential benefits of outstanding awards. Such actions may include, among other adjustments, but are not limited to, adjustments to the aggregate number of shares available for issuance under the 2025 Plan, the annual per participant limits, the number and kind of shares subject to outstanding award, and the exercise price of any outstanding Options or SARs, as well as any other appropriate adjustments it deems necessary, including as described in the 2025 Plan.

Amendment and Termination

The Board is permitted, at any time, to amend or terminate the 2025 Plan, and the Board or the Committee is permitted, at any time, to amend any award outstanding thereunder, provided that no amendment or termination may, in the absence of written consent by the affected participant (or the participant’s beneficiary if the participant is no longer living